UNIGE document Scientific Article
previous document  unige:9298  next document
add to browser collection

Safety and efficacy of once-daily nevirapine dosing: a multicohort study

Vallier, Nathalie
Nguyen, Alain
Lange, J. M.
Battegay, Manuel
de Wolf, Frank
Reiss, Peter
Lima, V. D.
show hidden authors show all authors [1 - 13]
Published in Antiviral Therapy. 2009, vol. 14, no. 7, p. 931-938
Abstract BACKGROUND: Nevirapine (NVP) is often prescribed once daily in clinical practice in combination with a once daily nucleoside backbone. We investigated the relationship of NVP dosing with safety and efficacy. METHODS: Patients from the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort study, Canadian HAART Observational Medical Evaluation and Research (HOMER) cohort and Swiss HIV Cohort Study (SHCS) using NVP-based combination therapy either once daily or twice daily were included. Risk factors for discontinuing NVP because of hypersensitivity reactions (HSRs) were investigated using multivariate logistic regression. Risk factors for virological failure 96 weeks after NVP initiation were identified using logistic regression and Cox models. RESULTS: Of 5,636 patients (774 once daily and 4,862 twice daily), 268 (4.8%) discontinued NVP because of HSR between 2 and 18 weeks. Logistic regression showed that, compared with patients with detectable HIV type-1 (HIV-1) RNA starting twice-daily NVP, there was a significantly higher risk of discontinuation of once-daily NVP because of HSR in patients with detectable HIV-1 RNA at the start of NVP (odds ratio [OR] 1.52; P=0.04), whereas the risk was actually significantly lower in patients starting once-daily NVP with undetectable HIV-1 RNA (OR 0.44; P=0.04). Cox models showed that risk of virological failure was not different for twice- versus once-daily NVP in treatment-naive patients (twice-daily versus once-daily hazard ratio [HR] 1.01; P=0.95), treatment-experienced patients experiencing treatment failure (twice-daily versus once-daily HR 1.22; P=0.30) or patients with undetectable HIV-1 RNA simplifying treatment with NVP (twice-daily versus once-daily HR 1.29; P=0.30). CONCLUSIONS: Initiation of a once-daily NVP-based regimen in patients with suppressed viraemia carries a low risk of treatment-limiting HSR. Once- or twice-daily NVP-based regimens appear to have similar antiretroviral efficacy.
Keywords Adenine/analogs & derivatives/therapeutic useAdultAnti-HIV Agents/administration & dosage/adverse effectsCohort StudiesDrug Administration ScheduleDrug Hypersensitivity/etiologyDrug Therapy, CombinationFemaleHIV Infections/ drug therapyHIV-1/drug effectsHumansMaleMiddle AgedNevirapine/administration & dosage/adverse effectsPhosphonic Acids/therapeutic useRetrospective StudiesTreatment Outcome
PMID: 19918097
Full text
Research group Unité HIV (46)
(ISO format)
CALMY, Alexandra et al. Safety and efficacy of once-daily nevirapine dosing: a multicohort study. In: Antiviral Therapy, 2009, vol. 14, n° 7, p. 931-938. doi: 10.3851/IMP1418 https://archive-ouverte.unige.ch/unige:9298

468 hits

0 download


Deposited on : 2010-07-12

Export document
Format :
Citation style :